← Back to Search

Geriatric Co-Management for Gastrointestinal Cancer (REACH Trial)

N/A
Recruiting
Led By Nadine J McCleary, MD, MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with a gastrointestinal cancer, including: cancers of the esophagus, stomach, pancreas, liver, bile duct, ampulla, colon, rectum, or anus, as well as neuroendocrine tumors.
Patients who are age 70+ at time of initial consult at DF/BWCC
Must not have
Patients less than age 70 at time of initial consultation appointment with DF/BWCC.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial is testing how cancer care consultation with a geriatrician can improve outcomes for older adults with gastrointestinal malignancies.

Who is the study for?
This trial is for adults aged 70 or older who have been diagnosed with gastrointestinal cancers such as esophageal, stomach, pancreatic, liver, bile duct, ampulla, colon, rectum or anus cancer. They must be continuing care at DF/BWCC and speak English or Spanish.
What is being tested?
The REACH study is testing the effectiveness of geriatric co-management in improving health outcomes for elderly patients with various types of gastrointestinal cancers during their treatment process.
What are the potential side effects?
Since this trial involves management strategies rather than drugs or medical procedures directly affecting the body's biology, there are no direct side effects associated with traditional clinical interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a type of gastrointestinal cancer.
Select...
I am 70 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 70 years old at my first appointment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability of electronic fitness assessment questionnaire
Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants
Feasibility of electronic fitness assessment questionnaire (developed from Comprehensive Geriatric Assessment tool)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention Phase - Geriatric Co-ManagementExperimental Treatment1 Intervention
Eligible older adults age 70 and older who score "Pre-Frail" or "Frail" will be randomized 2:1 to be offered to meet with a study geriatrician for geriatric co-management in addition to their standard oncology care. Study geriatrician will assist with management of symptoms, additional comorbidities, polypharmacy, and social/emotional concerns in addition to physical care. Geriatrician can make referrals and recommendations for additional supportive services that may be beneficial for more vulnerable older adult patients.
Group II: Intervention Phase - Standard Oncology CareActive Control1 Intervention
This arm is for those older adult patients (age 70+) who score as "Pre-Frail" or "Frail" in the fitness assessment questionnaire and are NOT randomized to meet with the study geriatrician. These patients will be followed for the duration of the study as they proceed with their usual oncology care. Study team will evaluate a number of different measures and outcomes, the primary one being unplanned emergency and hospital visits during the course of the study.

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,100 Previous Clinical Trials
352,840 Total Patients Enrolled
Nadine J McCleary, MD, MPHPrincipal InvestigatorDana-Farber Cancer Institute
1 Previous Clinical Trials
59 Total Patients Enrolled

Media Library

Geriatric Co-Management Clinical Trial Eligibility Overview. Trial Name: NCT04674267 — N/A
Gastrointestinal Cancer Research Study Groups: Intervention Phase - Geriatric Co-Management, Intervention Phase - Standard Oncology Care
Gastrointestinal Cancer Clinical Trial 2023: Geriatric Co-Management Highlights & Side Effects. Trial Name: NCT04674267 — N/A
Geriatric Co-Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT04674267 — N/A
~22 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top